Skip to main content

Tabernanthe iboga Facts

Hallucinogen; Indole alkaloid; NMDA receptor antagonist

Description

''Iboga (Tabernanthe iboga'' Baillon, Apocynaceae) — eboka — is a West and Central African rainforest shrub whose root bark is consumed as a powerful psychoactive preparation. Its dominant alkaloid, ibogaine, acts on multiple brain systems simultaneously — including glutamate, opioid, nicotinic, and serotonin pathways.[1] This broad multi-system action produces prolonged visionary and dissociative states unlike any other known plant.

Subjective effects include vivid autobiographical visions, contact with perceived entities, intense body sensitivity, profound dissociation, and severe loss of coordination.[2] The experience is predominantly internal and dream-like, lasting 12–24 hours in the acute phase with residual effects persisting up to 72 hours.

Ibogaine does not produce physical dependence or compulsive redosing,[3] but the primary acute risk is cardiac — ibogaine slows heart repolarization in a way that can trigger fatal arrhythmias, particularly without continuous cardiac monitoring.[4] Co-administration with other heart-affecting drugs or certain antidepressants substantially amplifies this risk.

Dose and duration

No dose or duration recorded for any route.

Body and dependence

Acute toxicity
High
Chronic toxicity
Moderate
Physical dependence
None
Psychological dependence
Negligible
Withdrawal
None recorded
Compulsive redosing
Negligible

Tolerance

Builds
None
Fully resets after
Not recorded

Effectslikely at a common dose

Perception
Dreaming enhancement; Holotropic state; Sleep-transition hallucinations; Spatial disorientation; Vestibular distortion; +10 possible, including Visual haze / noise
Body
Dizziness; Insomnia; Motor control impairment; Nausea; Physical fatigue; Wakefulness; +20 possible, including Nystagmus (eye wobbles), Trembling, Vomiting
Thinking
Cognitive impairment; Introspection enhancement; Memory replays; +14 possible, including Confusion, Decision impairment, Information processing suppression
Feeling
none likely · 9 possible, including Anxiety, Dysphoria, Emotional lability
Self
none likely · 8 possible, including Social disconnection, Communication suppression, Depersonalization
Time
none likely · 2 possible, including Temporal disorientation
Awareness
Personal insight

Who shouldn't take it

Absolute
Pre-existing cardiac conditions; Concurrent QT-prolonging medications; CYP2D6 poor metabolizer genotype; Electrolyte abnormalities; Pregnancy; Pediatric populations; Active opioid maintenance therapy without supervised tapering
Relative
Psychotic spectrum disorders; Severe hepatic impairment

Combinations60 recorded

Lethal (1)
GHB, GBL
Dangerous (40)
Benzodiazepines; Buprenorphine, Kratom; Naltrexone; NSAIDs; THC; 5-HTP, Tryptophan; Alpha-2 adrenergic receptor antagonist; Amphetamines; Anticholinergics; Antihistamines; Atypical antipsychotics; Benzodiazepines, Barbiturates; Buspirone; Cannabis; Cannabis, THC; CBD; Dopamine agonists; DXM; Ephedrine, Pseudoephedrine; Gabapentin, Pregabalin; GHB, Baclofen; Ketamine, DXM, PCP; Lithium; Local anesthetics; and 16 more, see full page
Caution (15)
See full page: psychedex.org/substances/tabernanthe-iboga
Not graded (4)
Not listed never means safe.

Seek help immediately if

No emergency profile is recorded for this substance. Not recorded never means no risk.

988 Suicide & Crisis LifelineFireside Project: 62-FIRESIDE

Version r2 · Not medical advice

References

  1. [1]
    ^Hwu C et al., Sames D (2026) Deciphering Ibogaine's Matrix Pharmacology: Multiple Transporter Modulation at Serotonin Synapses — Journal of the American Chemical Society doi:10.1021/jacs.5c06325
  2. [2]
    ^González Espejito F et al., Bouso JC (2025) The Ibogaine Experience Scale (IES): Development and psychometric properties of a multidimensional measure of ibogaine's subjective effects — PloS one doi:10.1371/journal.pone.0333296
  3. [3]
    ^Belgers M, Leenaars M, Homberg JR, Ritskes-Hoitinga M, Schellekens AF, Hooijmans CR (2016) Ibogaine and addiction in the animal model, a systematic review and meta-analysis — Translational psychiatry doi:10.1038/tp.2016.71
  4. [4]
    ^Koenig X, Hilber K (2015) The anti-addiction drug ibogaine and the heart: a delicate relation — Molecules doi:10.3390/molecules20022208
Print version
Report an issue